Examples of 'vorapaxar' in a sentence
Meaning of "vorapaxar"
Vorapaxar is a drug used for preventing blood clots and heart attacks. In English, it is used as a noun to refer to the medication
Show more definitions
- A thrombin receptor used to treat patients with a history of myocardial infarction or with peripheral arterial disease.
How to use "vorapaxar" in a sentence
Basic
Advanced
vorapaxar
Zontivity contains the active substance vorapaxar.
Effects of vorapaxar on other medicinal products.
The active substance is vorapaxar sulfate.
Vorapaxar was not mutagenic or genotoxic in a battery of in vitro and in vivo studies.
Platelet inhibition with vorapaxar is gradual and reversible.
Vorapaxar showed the most promising result among patients with a history of heart attack.
It is not known whether vorapaxar is excreted in human breast milk.
Vorapaxar has shown positive results in the phase II trials.
There are no reliable data on the use of vorapaxar in pregnant women.
Vorapaxar inhibits thrombin-induced platelet aggregation in in vitro studies.
Hazard Ratio is vorapaxar group versus placebo group.
Vorapaxar is eliminated primarily in the form of metabolites, with no vorapaxar detected in urine.
Atopaxar and Vorapaxar.
Therefore, vorapaxar should not be used with prasugrel or ticagrelor.
The mean volume of distribution of vorapaxar is approximately 424 litres.
See also
Vorapaxar is eliminated primarily by metabolism by the CYP3A enzymes.
Studies in rats have shown vorapaxar and / or its metabolites are excreted in milk.
Vorapaxar is eliminated primarily by metabolism, with significant contribution by CYP3A.
Zontivity 2 mg tablets Vorapaxar.
Vorapaxar Serum concentrations may be increased due to CYP3A inhibition by.
Each tablet contains 2.08 mg of vorapaxar as vorapaxar sulfate.
Vorapaxar had no effect on the QTc interval at single doses up to 120 mg.
The mean absolute bioavailability of vorapaxar from the 2.5 mg dose of vorapaxar sulfate is 100.
Vorapaxar should not be used with prasugrel or ticagrelor see section 4.2.
Pharmacokinetics of vorapaxar are similar between elderly, including those ≥ 75 years of age, and younger patients.
Vorapaxar did not increase bleeding time in non-human primates when administered alone at 1 mg / kg.
In addition, vorapaxar inhibits thrombin receptor agonist peptide ( TRAP ) - induced platelet aggregation without affecting coagulation parameters.
Vorapaxar blocks the PAR-1 receptors ( known as ‘ thrombin receptors ' ) on the surface of the platelets.
Vorapaxar is a weak inhibitor of the intestinal P-glycoprotein ( P-gp ) transporter.
